ReviewFrontiers in immunology2019
Pulmonary Manifestations of Primary Sjögren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 82 citations in OpenAlex.
- IFN-γ-Associated Signaling Networks in Interstitial Lung Disease Associated With Sjögren's Disease.Immunity, inflammation and disease · 2026Review
- Eosinophilic Bronchiolitis Diagnosed by a Transbronchial Lung Cryobiopsy and Successfully Treated with Biologic Agents: A Report of Two Cases and Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- Pulmonary Manifestations of Sjögren's Syndrome: A Case Report and Review of the Literature.Cureus · 2026Article
- The Role of Imaging Techniques in the Evaluation of Extraglandular Manifestations in Patients with Sjögren's Syndrome.Diagnostics (Basel, Switzerland) · 2026Review
- Clinical features, diagnosis, and treatment of primary Sjögren's disease with interstitial lung disease: A narrative review.Frontiers in immunology · 2026Review
- Insights into Pulmonary Arterial Hypertension in Connective Tissue Diseases.Journal of clinical medicine · 2025Review
- The Role of Anti-SSB/La Antibodies as Predictors of Decreased Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) in Primary Sjögren Disease.International journal of molecular sciences · 2025Article
- Bronchiolar disorders in systemic autoimmune rheumatic diseases.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Clinical Characteristics and Risk Factors for Progressive Pulmonary Fibrosis in Primary Sjögren's Syndrome: A Case-Control Study.Risk management and healthcare policy · 2025Article
- Article
- Successful Immunosuppressive Therapy for Interstitial Lung Disease Associated with Sjögren's Syndrome with Double-positive Anti-SS-A and Anti-centromere Antibodies.Internal medicine (Tokyo, Japan) · 2024Article
- The interplay between rheumatic diseases and pulmonary health.Rheumatology international · 2024Review
- Clinical Characteristics and Outcomes of Interstitial Lung Disease in Primary Sjögren's Syndrome: A Retrospective Cohort Study.Mediterranean journal of rheumatology · 2024Article
- Primary Sjogren's syndrome presenting as ptosis and eyelid swelling: A case report.Clinical case reports · 2024Article
- Quantification of autoantibodies using a luminescent profiling method in autoimmune interstitial lung disease.Frontiers in immunology · 2024Article
- Serum biomarker-based risk model construction for primary Sjögren's syndrome with interstitial lung disease.Frontiers in molecular biosciences · 2024Article
- Tofacitinib in the treatment of primary Sjögren's syndrome-associated interstitial lung disease: study protocol for a prospective, randomized, controlled and open-label trial.BMC pulmonary medicine · 2023Article
- The Role of Small Airway Disease in Pulmonary Fibrotic Diseases.Journal of personalized medicine · 2023Review
- The Spectrum of Extraglandular Manifestations in Primary Sjögren's Syndrome.Journal of personalized medicine · 2023Review
- Melatonin: a potential therapeutic approach for the management of primary Sjögren's syndrome.Immunologic research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary involvement in primary Sjögren's syndrome (pSS) is an understudied entity with important clinical implications. Its prevalence has been reported in up to 20% of pSS patients. Pulmonary manifestations of pSS are diverse with involvement of airway and/or lung parenchyma. Histopathology of lung lesions suggests a predominance of submucosal mononuclear cell infiltration consisting predominantly of CD4+ T cells. Current understanding of the pathophysiology of lung disease in pSS suggests a similar process driving the pulmonary process as those in the salivary glands, with epithelial cells playing a critical role in the initiation, maintenance, and symptomatology of the disease. Clinical manifestations of lung involvement in pSS are as varied as the underlying pathology and can be vague and non-specific, thus delaying diagnosis. Management options depend on the underlying pathology but are generally limited due to lack of systematic randomized controlled trials. This review helps summarize our current understanding of lung involvement in pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.